Literature DB >> 10921480

Impaired coronary microvascular function in diabetics.

G Tsujimoto1.   

Abstract

Global and regional myocardial uptake was determined with technetium-99m tetrofosmin and a 4 hour exercise (370 MBq i.v.) and rest (740 MBq i.v.) protocol, in 24 patients with non-insulin dependent diabetes mellitus and in 22 control subjects. The purpose of this study was to evaluate impaired coronary microvascular function in diabetics by measurement of % uptake increase in myocardial counts. The parameter of % uptake increase (deltaMTU) was calculated as the ratio of exercise counts to rest myocardial counts with correction of myocardial uptake for dose administered and physical decay between the exercise study and the rest study. Global deltaMTU was significantly lower in the diabetics than in control subjects (14.4 +/- 5.4% vs. 21.7 +/- 8.5%, p < 0.01). Regional deltaMTU in each of 4 left ventricular regions (anterior, septal, inferior, posterolateral) was significantly lower in the diabetic group than in the control group (p < 0.01) respectively, but there were no significant differences between deltaMTU in the 4 left ventricular regions in the same group. deltaMTU was useful as a non-invasive means of evaluating impaired coronary microvascular function in diabetics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10921480     DOI: 10.1007/bf02987855

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  2 in total

1.  Abnormal myocardial perfusion in the absence of anatomically significant coronary artery disease: implications and clinical significance.

Authors:  Shreenidhi M Venuraju; Ajay Yerramasu; Avijit Lahiri
Journal:  J Nucl Cardiol       Date:  2009-09-10       Impact factor: 5.952

2.  The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin.

Authors:  J E Tooke; L M Elston; K M Gooding; C I Ball; D M Mawson; J Piper; R Sriraman; R Urquhart; A C Shore
Journal:  Diabetologia       Date:  2006-03-01       Impact factor: 10.122

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.